US Patent

US11957694 — Orodispersible dosage unit containing an estetrol component

Formulation · Assigned to Estetra SRL · Expires 2036-06-17 · 10y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an orodispersible solid pharmaceutical dosage unit containing at least 100 μg of an estetrol component.

USPTO Abstract

An orodispersible solid pharmaceutical dosage unit of estetrol is disclosed. The solid dosage unit is easy to manufacture and suited for sublingual, buccal or sublabial administration. The orodispersible solid pharmaceutical dosage unit can include at least 100 μg of an estetrol component and pharmaceutically acceptable excipients. Methods of manufacturing the orodispersible solid pharmaceutical dosage unit are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
US11957694
Jurisdiction
US
Classification
Formulation
Expires
2036-06-17
Drug substance claim
No
Drug product claim
Yes
Assignee
Estetra SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.